Mefloquine targets NLRP3 to reduce lipopolysaccharide‐induced systemic inflammation and neural injury
The EMBO Reports · 09.10.2023 · 24 (10)
DOI: 10.15252/embr.202357101 ↗Kurz gefasst
Fachartikel in der Zeitschrift The EMBO Reports, online erschienen am 25.08.2023. Verfasst von Si-Yuan Jiang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology, Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Mefloquine, Lipopolysaccharides, Inflammation. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: MOST | National Natural Science Foundation of China (NSFC), National Key R&D Program of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology, Nanjing Medical University, Nanjing, China.
- Department of Pharmacology, Nanjing University of Chinese Medicine, Nanjing, China.
ORCID-Profile: Ren-Hong Du, Yang Liu, Ming Lu
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
- National Key R&D Program of China
Zitieren
APA
Jiang, S. Y., Tian, T., Li, W. J., Liu, T., Wang, C., Hu, G., Du, R. H., Liu, Y., & Lu, M. (2023). Mefloquine targets NLRP3 to reduce lipopolysaccharide‐induced systemic inflammation and neural injury. The EMBO Reports, 24(10). https://doi.org/10.15252/embr.202357101
Vancouver
Jiang SY, Tian T, Li WJ, Liu T, Wang C, Hu G, et al. Mefloquine targets NLRP3 to reduce lipopolysaccharide‐induced systemic inflammation and neural injury. The EMBO Reports. 2023;24(10). doi:10.15252/embr.202357101
BibTeX
@article{Jiang2023,
author = {Jiang, Si-Yuan and Tian, Tian and Li, Wen-Jie and Liu, Ting and Wang, Cong and Hu, Gang and Du, Ren-Hong and Liu, Yang and Lu, Ming},
title = {Mefloquine targets NLRP3 to reduce lipopolysaccharide‐induced systemic inflammation and neural injury},
journal = {The EMBO Reports},
year = {2023},
volume = {24},
number = {10},
doi = {10.15252/embr.202357101}
}
EUVIMED